75 related articles for article (PubMed ID: 10746804)
1. Long-term effects of rhEPO therapy on erythrocyte rheology in dialysis patients with different target hematocrits.
Paulitschke M; Ludat K; Riedel E; Hampl H
Clin Nephrol; 2000 Feb; 53(1 Suppl):S36-41. PubMed ID: 10746804
[TBL] [Abstract][Full Text] [Related]
2. [Improvement of hemorheologic parameters in hemodialyzed patients treated with human recombinant erythropoietin].
Delamaire M; Durand F; Hamel D; Joyeux V; Lepogamp P; Genetet B
J Mal Vasc; 1991; 16(3):289-94. PubMed ID: 1940657
[TBL] [Abstract][Full Text] [Related]
3. Complete correction of renal anemia by recombinant human erythropoietin.
Ludat K; Paulitschke M; Riedel E; Hampl H
Clin Nephrol; 2000 Feb; 53(1 Suppl):S42-9. PubMed ID: 10746805
[TBL] [Abstract][Full Text] [Related]
4. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?
de Fijter CW; Popp-Snijders C; Oe LP; Tran DD; van der Meulen J; Donker AJ
Haematologica; 1995; 80(4):332-4. PubMed ID: 7590502
[TBL] [Abstract][Full Text] [Related]
5. Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients?
Sommerburg O; Grune T; Hampl H; Riedel E; Ehrich JH; Siems WG
Clin Nephrol; 2000 Feb; 53(1 Suppl):S23-9. PubMed ID: 10746802
[TBL] [Abstract][Full Text] [Related]
6. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of renal anemia with recombinant human erythropoietin].
Burghard R; Gordjani N; Leititis JU
Monatsschr Kinderheilkd; 1989 Mar; 137(3):174-7. PubMed ID: 2716749
[TBL] [Abstract][Full Text] [Related]
8. Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study.
Krafft A; Breymann C
J Obstet Gynaecol Res; 2011 Feb; 37(2):119-24. PubMed ID: 21159035
[TBL] [Abstract][Full Text] [Related]
9. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
10. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
[TBL] [Abstract][Full Text] [Related]
11. Effects of erythropoietin on erythrocyte deformability in non-transfused preterm infants.
Klipp M; Holzwarth AU; Poeschl JM; Nelle M; Linderkamp O
Acta Paediatr; 2007 Feb; 96(2):253-6. PubMed ID: 17429915
[TBL] [Abstract][Full Text] [Related]
12. The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors.
Biesma DH; Bronkhorst PJ; de Groot PG; van de Wiel A; Kraaijenhagen RJ; Marx JJ
J Lab Clin Med; 1994 Jul; 124(1):42-7. PubMed ID: 8035101
[TBL] [Abstract][Full Text] [Related]
13. Blood rheology in hemodialysis patients treated with recombinant human erythropoietin.
Brunner R; Pollok M; Heidel M; Müller R; Degenhardt S; Baldamus CA
Contrib Nephrol; 1989; 76():306-12; discussion 312-4. PubMed ID: 2582784
[No Abstract] [Full Text] [Related]
14. Effect of erythropoietin treatment on tissue oxygenation in patients with severe transfusion dependent renal anaemia.
Landgraf H; Grützmacher P; Garcia-Bartels C; Bergmann M; Ehrly AM; Schoeppe W
Eur J Med; 1993; 2(7):393-7. PubMed ID: 8258026
[TBL] [Abstract][Full Text] [Related]
15. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
16. Blood rheology and 2,3-diphosphoglycerate levels after erythropoietin treatment.
Crowley JP; Chazan JA; Metzger JB; Pono L; Valeri CR
Ann Clin Lab Sci; 1993; 23(1):24-32. PubMed ID: 8430997
[TBL] [Abstract][Full Text] [Related]
17. Impaired erythrocyte fluidity during treatment of renal anaemia with erythropoietin.
Linde T; Sandhagen B; Danielson BG; Wikström B
J Intern Med; 1992 Jun; 231(6):601-6. PubMed ID: 1619383
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
19. The effect of erythropoietin on lactate, pyruvate and excess lactate under physical exercise in dialysis patients.
Meierhenrich R; Jedicke H; Voigt A; Lange H
Clin Nephrol; 1996 Feb; 45(2):90-7. PubMed ID: 8846536
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin, folic acid deficiency and hyperhomocysteinemia: is there a possible relationship in chronically hemodialyzed patients?
Korzets A; Ori Y; Chagnac A; Weinstein T; Herman M; Zevin D; Malachi T; Gafter U
Clin Nephrol; 2000 Jan; 53(1):48-54. PubMed ID: 10661482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
